Investing.com - Financial Markets Worldwide

Foresee Pharmaceuticals Co Ltd (6576)

TPEX
Currency in TWD
81.70
+0.30(+0.37%)
Closed·
6576 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
6576 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
81.6082.60
52 wk Range
57.7086.90
Key Statistics
Edit
Bid/Ask
103.50 / 104.00
Prev. Close
83.4
Open
82.6
Day's Range
81.6-82.6
52 wk Range
57.7-86.9
Volume
168.71K
Average Volume (3m)
141.95K
1-Year Change
2.26%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
6576 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
126.50
Upside
+54.83%
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 13
RSI suggests the stock is in overbought territory
Unlock InvestingPro

Foresee Pharmaceuticals Co Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Foresee Pharmaceuticals Co Ltd Company Profile

Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.

Industry
Biotechnology & Medical Research
Sector
Healthcare
0
Market
Taiwan

Compare 6576 to Peers and Sector

Metrics to compare
6576
Peers
Sector
Relationship
P/E Ratio
−8.9x−18.0x−0.6x
PEG Ratio
0.170.140.00
Price/Book
13.0x2.7x2.6x
Price / LTM Sales
28.6x6.7x3.3x
Upside (Analyst Target)
55.4%0.0%39.0%
Fair Value Upside
Unlock−12.3%4.9%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 126.50
(+54.83% Upside)

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
-2.14 / -1.28
Revenue / Forecast
111.65M / 132.00M
EPS Revisions
a
a
Unlock
Last 90 days

6576 Income Statement

FAQ

What Stock Exchange Does Foresee Pharmas Trade On?

Foresee Pharmas is listed and trades on the Taipei Exchange stock exchange.

What Is the Stock Symbol for Foresee Pharmas?

The stock symbol for Foresee Pharmas is "6576."

What Is the Foresee Pharmas Market Cap?

As of today, Foresee Pharmas market cap is 12.60B.

What Is Foresee Pharmas's Earnings Per Share (TTM)?

The Foresee Pharmas EPS (TTM) is -9.69.

When Is the Next Foresee Pharmas Earnings Date?

Foresee Pharmas will release its next earnings report on 06 Nov 2025.

From a Technical Analysis Perspective, Is 6576 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Foresee Pharmas Stock Split?

Foresee Pharmas has split 3 times.

How Many Employees Does Foresee Pharmas Have?

Foresee Pharmas has 0 employees.

What is the current trading status of Foresee Pharmas (6576)?

As of 26 Aug 2025, Foresee Pharmas (6576) is trading at a price of 81.70, with a previous close of 83.40. The stock has fluctuated within a day range of 81.60 to 82.60, while its 52-week range spans from 57.70 to 86.90.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.